Linked Life Data

16728219

Source:http://linkedlifedata.com/resource/pubmed/id/16728219

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2006-5-26
pubmed:abstractText
Clinical outcomes after multivessel versus single-vessel percutaneous coronary intervention (PCI) in the era of stents, glycoprotein IIb/IIIa inhibitors, and clopidogrel pretreatment have not been well studied. Thus, we compared outcomes from the Do Tirofiban and ReoPro Give Similar Efficacy Outcome Trial (TARGET) for patients who underwent multivessel versus single-vessel PCI and separately considered the effect of acute coronary syndromes on the results. Composite clinical outcomes (death, myocardial infarction, and target vessel revascularization) were evaluated at 30 days and 6 months and mortality at 1 year. Safety analysis included in-patient major and minor bleeding. Despite similar baseline characteristics, patients who underwent multivessel PCI (n = 775) had significantly higher 30-day and 6-month composite event rates than did those who were treated in a single coronary artery territory (n = 3,969). This association remained significant at 30 days (hazard ratio 1.57, 95% confidence interval 1.06 to 2.33, p = 0.025) after using propensity matching to minimize confounding factors. The higher event rate was primarily due to an increase in periprocedural myocardial infarction. However, there were no significant differences in propensity-matched ischemic outcomes at 6 months and 1 year or in bleeding. In addition, in a propensity-matched analysis that included 810 patients with acute coronary syndrome, multivessel stenting resulted in numerically more ischemic events than did single-vessel stenting, although this did not reach statistical significance (hazard ratio 1.32, 95% confidence interval 0.85 to 2.05, p = 0.221). In conclusion, multivessel PCI was more often associated with periprocedural myocardial infarction than single-vessel intervention, although this did not translate into higher 1-year mortality. A randomized trial comparing multivessel PCI with staged or surgical revascularization is warranted.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
97
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1585-90
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:16728219-Angioplasty, Balloon, Coronary, pubmed-meshheading:16728219-Antibodies, Monoclonal, pubmed-meshheading:16728219-Blood Vessel Prosthesis Implantation, pubmed-meshheading:16728219-Coated Materials, Biocompatible, pubmed-meshheading:16728219-Coronary Disease, pubmed-meshheading:16728219-Double-Blind Method, pubmed-meshheading:16728219-Female, pubmed-meshheading:16728219-Follow-Up Studies, pubmed-meshheading:16728219-Humans, pubmed-meshheading:16728219-Immunoglobulin Fab Fragments, pubmed-meshheading:16728219-Male, pubmed-meshheading:16728219-Middle Aged, pubmed-meshheading:16728219-Platelet Aggregation Inhibitors, pubmed-meshheading:16728219-Platelet Glycoprotein GPIIb-IIIa Complex, pubmed-meshheading:16728219-Stents, pubmed-meshheading:16728219-Survival Rate, pubmed-meshheading:16728219-Treatment Outcome, pubmed-meshheading:16728219-Tyrosine
pubmed:year
2006
pubmed:articleTitle
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
pubmed:affiliation
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Research Support, N.I.H., Extramural